BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 19152839)

  • 1. Targeting virulence: a new paradigm for antifungals.
    Gauwerky K; Borelli C; Korting HC
    Drug Discov Today; 2009 Feb; 14(3-4):214-22. PubMed ID: 19152839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetics of medically important fungi.
    Whelan WL
    Crit Rev Microbiol; 1987; 14(2):99-170. PubMed ID: 3549159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis.
    Goldman RC; Frost DJ; Capobianco JO; Kadam S; Rasmussen RR; Abad-Zapatero C
    Infect Agents Dis; 1995 Dec; 4(4):228-47. PubMed ID: 8665087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
    Steinbach WJ; Reedy JL; Cramer RA; Perfect JR; Heitman J
    Nat Rev Microbiol; 2007 Jun; 5(6):418-30. PubMed ID: 17505522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts.
    Bastert J; Schaller M; Korting HC; Evans EG
    Int J Antimicrob Agents; 2001 Feb; 17(2):81-91. PubMed ID: 11165110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antifungal resistance in opportunistic pathogenic fungi (I). Polyenes and fluorocytosine].
    Martínez-Suárez JV; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 1996; 14(6):384-9. PubMed ID: 8756218
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress and prospects for targeting Hsp90 to treat fungal infections.
    Veri A; Cowen LE
    Parasitology; 2014 Aug; 141(9):1127-37. PubMed ID: 24560124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory properties of antifungal agents on phagocytic cells.
    Simitsopoulou M; Roilides E; Walsh TJ
    Immunol Invest; 2011; 40(7-8):809-24. PubMed ID: 21985307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New targets and delivery systems for antifungal therapy.
    Walsh TJ; Viviani MA; Arathoon E; Chiou C; Ghannoum M; Groll AH; Odds FC
    Med Mycol; 2000; 38 Suppl 1():335-47. PubMed ID: 11204162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of new antifungals on the etiology of invasive fungal infections: emergence, resistance and breakthrough infection].
    Salavert M; Jarque I
    Rev Esp Quimioter; 2006 Mar; 19(1):11-3. PubMed ID: 16688286
    [No Abstract]   [Full Text] [Related]  

  • 11. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
    Pfaller MA; Diekema DJ
    J Clin Microbiol; 2004 Oct; 42(10):4419-31. PubMed ID: 15472288
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing?
    Vazquez JA
    Clin Infect Dis; 2008 Jun; 46(12):1889-901. PubMed ID: 18466092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspartic proteinases of Candida spp.: role in pathogenicity and antifungal resistance.
    Silva NC; Nery JM; Dias AL
    Mycoses; 2014 Jan; 57(1):1-11. PubMed ID: 23735296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs.
    Blankenship JR; Steinbach WJ; Perfect JR; Heitman J
    Curr Opin Investig Drugs; 2003 Feb; 4(2):192-9. PubMed ID: 12669381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug resistance in the treatment of invasive fungal infections].
    Nordøy I; Gaustad P
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2607-11. PubMed ID: 19023376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal agents, WO2009025733.
    Sudhir PV; Ranjan DS; Ganpat AN
    Expert Opin Ther Pat; 2010 Jan; 20(1):137-43. PubMed ID: 19874257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness.
    Anderson JB
    Nat Rev Microbiol; 2005 Jul; 3(7):547-56. PubMed ID: 15953931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview: antifungal combination therapy.
    Sugar AM
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1364-5. PubMed ID: 11890347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing epidemiology of systemic fungal infections.
    Richardson M; Lass-Flörl C
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new problem: multiresistant fungi].
    Wehr A
    Dtsch Med Wochenschr; 1997 Mar; 122(11):A9. PubMed ID: 9102278
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.